How to Read a Certificate of Analysis (CoA) for Research Peptides

A Certificate of Analysis (CoA) is a technical document that reports quality-control results for a specific batch of a synthetic peptide. It is issued by the manufacturer or, in stricter settings, by an independent third-party laboratory. Its minimum unit of information is the batch (LOT). Two vials of the same peptide synthesized weeks apart are different batches and require different CoAs. A generic CoA valid for 'any vial' of a product is not a CoA — it is a product datasheet.

The most common misreading is to treat the CoA as a binary quality stamp ('has CoA / no CoA'). In practice, the value of the document lives in the concrete numbers: what HPLC purity was reported for this specific lot, what mass the spectrometer observed, and whether the report carries a signature from the responsible analyst. A CoA without a traceable lot, without an attached chromatogram, and without a signature has limited evidentiary weight.

For a researcher who plans to publish, the CoA also serves a forensic role. If six months from now a reviewer asks why a HaCaT assay does not replicate, the CoA of the lot used is the first evidence to rule out variability caused by impurities. Without that paper, traceability breaks at the very first link.

A well-built CoA has a core of non-negotiable fields. Peptide name and one-letter sequence (e.g., H-Gly-His-Lys-OH for GHK). Lot number and synthesis date. Theoretical molecular weight, calculated from the sequence, and observed molecular weight, measured by mass spectrometry. HPLC purity (high-performance liquid chromatography), with detection wavelength stated — usually UV at 214 or 220 nm, where the peptide bond absorbs. Recommended storage conditions and an expiry or re-test date.

Optional but desirable fields: declared counter-ion (acetate, TFA), water content when relevant, and an endotoxin result when the peptide is destined for sensitive cell-culture work. One critical caveat: the counter-ion changes the actual mass of the dry powder. A peptide reported as 'acetate salt' may carry 5–15% of its weight as acetate, which directly distorts molar concentration calculations if ignored.

The field worth looking at twice is the attached HPLC chromatogram, not just the purity number. A 98% can hide one large neighboring peak (a structurally close impurity, hard to separate) or several small peaks scattered across the trace (a mixture). For sensitive assays the chromatogram pattern matters as much as the headline number.

Identity verification is done by comparing the theoretical molecular weight (calculated from the sequence) with the mass observed by mass spectrometry, typically ESI-MS (electrospray ionization) or MALDI-TOF (matrix-assisted laser desorption/ionization, time-of-flight). On high-resolution instruments, a difference under 0.1 Da between theoretical and observed mass is treated as an identity match. On lower-resolution instruments, the classical tolerance is ±1 Da.

A technical detail that often confuses newer researchers: the mass shown on a spectrum is usually the protonated molecular ion [M+H]+ or a multiply-charged ion [M+nH]n+, not the neutral mass. The CoA should report the deconvoluted neutral mass, but it pays to look at the attached spectrum. If the main ion matches and the isotopic envelope fits the molecular formula, identity is confirmed. Side peaks at +16 Da (methionine oxidation), +22 Da (sodium adduct), or −18 Da (dehydration) are useful information the headline purity does not always capture.

For larger peptides (>30 amino acids) or labile modifications, MALDI-TOF tends to give cleaner signal; for small and medium peptides, ESI is the standard. Either method is acceptable provided the observed mass falls within tolerance and the method used is declared on the CoA.

Reversed-phase HPLC purity is calculated as the peak area of the target peptide divided by the total peak area across the chromatogram, expressed as a percentage. Standard detection is UV at 214 nm, where the backbone amide bond absorbs, giving a response roughly proportional to the peptide mass of each species in the run.

A 98% purity means that 98% of the peptide material detectable by UV corresponds to the target product. It does not measure salts, residual water, or endotoxins. That is why a peptide at 99% HPLC can still legitimately carry 10% acetate as counter-ion — these are independent metrics. For preclinical research the defensible practice is to work at ≥98% purity, and in assays especially sensitive to structural impurities (competitive binding, kinetic enzyme studies) to aim for ≥99%.

A 1–2% impurity may sound trivial, but if it is a truncated variant that retains partial affinity for the same target, it can contaminate results disproportionately. Beyond the headline number, look at whether the reported impurities are random (synthesis noise) or systematic (always one peak close to the product), the latter indicating a reproducible by-product of the synthesis.

A CoA signed by the responsible analyst or by the laboratory's QC head carries different documentary weight than an auto-generated PDF. A signature means an identifiable person stands behind the reported data; in audits, reviews, or disputes, that matters. International best practice inspired by ICH Q6B treats this chain of accountability as part of the quality system, not a clerical detail.

For reproducibility, the rule is simple: in the Methods section of any publication or preprint, the lot number should appear alongside the peptide name and supplier. 'GHK-Cu sourced from Supplier X, LOT 240315, HPLC purity 99.2%, identity confirmed by ESI-MS' is replicable information. 'GHK-Cu from Supplier X' is not — later batches may carry different purities, counter-ions, or systematic impurity profiles.

This practice is still not universal in the peptide research literature, and it is one of the quiet causes of irreproducibility. Reporting the LOT is not bureaucratic hygiene. It is the difference between another lab being able to confirm your finding or not.

It helps to scope what the document is and is not. A CoA reports the state of the peptide at the moment of post-synthesis analysis. It does not certify integrity after shipping, conservation during transit, or behavior once reconstituted. Cold-chain, freeze-thaw cycles, and exposure to UV light or humidity all happen after the CoA was issued and are the end user's responsibility.

It also does not cover interactions with the experimental matrix. A peptide can be 99.5% pure and still lose activity through adsorption to plastic walls at nanomolar concentrations, oxidation if it carries free methionine or cysteine, or aggregation in inadequate solvents. These are design variables, not batch defects.

Finally, no CoA turns a research peptide into a clinical product. These materials are Research Use Only. Any biological reference in this article points to in vitro or animal-model observations reported in the preclinical literature, not to recommendations for human use.